The Instituto Português de Oncologia Francisco Gentil, also known as the Instituto Português de Oncologia, Portuguese for Portuguese Oncology Institute, is a state-run cancer hospital and research organization in Portugal. The I.P.O. has autonomous regional branches in Lisbon, Porto and Coimbra.

During the past decade, IPO de Lisboa; Servico de Oncologia Medica conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "IPO de Lisboa; Servico de Oncologia Medica" #1 collaborator was "SOLTI Breast Cancer Research Group" with 2 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "IPO de Lisboa; Servico de Oncologia Medica" are "Breast Cancer" (4 trials), "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer" (1 trials), "Malignant Melanoma" (1 trials), "Melanoma" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "IPO de Lisboa; Servico de Oncologia Medica" in a lesser frequency.

Most popular intervention types in "IPO de Lisboa; Servico de Oncologia Medica" are "Drug" (11 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Atezolizumab" (3 trials), "Vemurafenib" (3 trials), "Letrozole" (2 trials) and "Taselisib" (2 trials). Other intervention names were less common.

The vast majority of trials in "IPO de Lisboa; Servico de Oncologia Medica" are 7 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "IPO de Lisboa; Servico de Oncologia Medica". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in IPO de Lisboa; Servico de Oncologia Medica, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IPO de Lisboa; Servico de Oncologia Medica, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".